What's New in the Guidelines

Updated
Reviewed
Apr. 12, 2022

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format that can be updated easily as relevant changes in prevention and treatment recommendations occur.

The editors and subject-matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information.

All changes are developed by the subject-matter groups listed in the document (changes in group composition also are posted promptly). These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows:

What’s New

April 12, 2022

Key updates to the guidelines include the following:

Bacterial Enteric Infections

  • Updated information on the management and treatment of Clostridioides difficile (C. difficile) disease now aligned with the recent Infectious Diseases Society of America guidelines.
  • Expanded discussion of the role of fidaxomicin and bezlotoxumab in the therapy of C. difficile disease.

February 17, 2022

Key updates to the guidelines include the following:

Mycobacterium tuberculosis

  • Updated references and rationales.
  • Updated drug–drug interactions.
  • Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy.
  • Clarified that, for the treatment of drug-resistant tuberculosis, it is possible to use drug regimens with total duration as short as 6 to 12 months total when bedaquiline is part of the regimen instead of the 18 to 20 months total duration suggested by other sources.

November 18, 2021

Key updates to the guidelines include the following:

Appendix B: Panel Roster and Financial Disclosures

  • Updated member conflict of interest information for 2021-2022.
  • Updated roster to include 22 new members, 6 new Section Group Leads and 1 new Leadership member.

Immunizations

  • The immunizations section has been updated to reflect the recommendation that all people with HIV should receive the COVID-19 vaccine regardless of their CD4 T lymphocyte count or HIV viral load.
  • People with advanced or untreated HIV who received a 2-dose series with one of the mRNA COVID-19 vaccines should receive a third dose of that vaccine at least 28 days after the second dose.
  • The zoster vaccine is now recommended for people with HIV age 18 years old and older in alignment with Advisory Committee on Immunization Practices (ACIP) recommendations. 

 

Download Guidelines